Board of Directors
Robert Ingram has served on Novan’s Board of Directors since 2011 and was named Chairman in February 2016. Mr. Ingram is a general partner of Hatteras Venture Partners. Prior to Hatteras Venture Partners, he held the roles of Chief Executive Officer and Chairman of the Board of GlaxoWellcome until his retirement in 2009 when he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline, plc. (NYSE:GSK). Mr. Ingram has numerous board engagements, including lead director of Valeant Pharmaceuticals International (NASDAQ:VRX) and Chairman of Viamet Pharmaceuticals, Inc. He is also a member of the Board of Directors of Malin Corporation plc. (Dublin:MLC) and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and lead director of Cree, Inc. (NASDAQ:CREE).
W. Kent Geer is a former audit partner (retired) with Ernst & Young, LLP. His 37 year career spans an extensive track record in serving numerous public and private companies in a variety of industries including biotechnology, pharmaceuticals and other technology companies. During his tenure, Mr. Geer was the audit practice leader for the Ernst & Young Entrepreneurial Services Group in Raleigh, North Carolina and was the market team leader for the technology industry practice of the Carolinas. Beginning in 2012, Mr. Geer served as the Chairman of the Board of PowerSecure International, Inc. (NYSE:POWR) until the successful sale of the company in May 2016.
Robert Keegan is the former Chief Executive Officer and Chairman of the Board of The Goodyear Tire & Rubber Company, roles that he held until his retirement in 2010. Most recently, he was an operating partner of the San Francisco-based private equity firm Friedman, Fleischer & Lowe. From 1972 to 2000, Mr. Keegan held various marketing, financial and managerial posts at Eastman Kodak, except for a two-year period from 1995 to 1997 when he worked as an Executive Vice President of the Avery Dennison Corporation. Mr. Keegan is Chairman of the Board of Loparex, Inc., serves on the boards of the Xerox Corporation (NYSE: XRX) and Fuqua Business School and the Heart Center of Duke University and is a partner of L&K Properties of North Carolina, LLC.
G. Kelly Martin is Chief Executive Officer of Malin Life Sciences Holding. He served as CEO of Elan, Ireland’s largest indigenous biotech company, from February 2003 until its successful $8.6 Billion sale to Perrigo Company in December 2013. Before joining Elan, Mr. Martin spent more than 20 years at Merrill Lynch & Co., Inc., where he held a broad array of operating and executive responsibilities. Mr. Martin also serves as a non-executive director on a number of public and private company boards and is a co-founder and director of Brandon Point Industries.
Sean Murphy is a non-executive director of Malin Life Sciences Holding and the former Head of Corporate M&A and Business Development at Abbott Laboratories. He is also a senior adviser at Evercore Partners, a leading investment banking advisory firm. In a career that spans over thirty years, Mr. Murphy’s experience in the life sciences sector is both operational and transactional, having run Abbott’s vascular business and played a leading role in a number of strategic investments during his tenure. Mr. Murphy is also a director of Brandon Point Industries and Immucor. Mr. Murphy is a CPA, State of Illinois.
Dr. Palmour is a Co-founder, the Chief Technology Officer, Power & RF, and a Vice President of Cree, Inc. Dr. Palmour has authored or co-authored more than 360 publications and is a co-inventor on 65 U.S. patents and 150 corresponding foreign patents. He has been a Program Manager or Principal Investigator on government research contracts to Cree totaling more than $160 million. Having served as a member of the Board of Directors of Cree for fifteen years, Dr. Palmour has extensive experience and expertise in advancing innovation to broad-scale product commercialization.
Machelle Sanders is a seasoned executive with over 29 years of progressive pharmaceutical and biotechnology experience. Ms. Sanders is Secretary of the N.C. Department of Administration, appointed by Governor Roy Cooper. In the private sector, Ms. Sanders was most recently responsible for the pharmaceutical operations and technology operational strategy for Biogen’s multiple sclerosis (MS) franchise (i.e. AVONEX™, PLEGRIDY™, TECFIDERA™, and TYSABRI™). She held the title of vice president of manufacturing and general manager of the company’s largest and most advanced manufacturing facility in Research Triangle Park, North Carolina. Ms. Sanders has also held leadership positions in manufacturing, global quality assurance and quality control at Biogen, Purdue Pharmaceuticals, and Diosynth-Akzo Nobel. She holds a bachelor of science degree in Biochemistry from North Carolina State University and a masters of health administration (MHA) from Pfeiffer University.
Paula Brown Stafford, MPH, is the Chief Development Officer for Novan. Prior to joining Novan, she served as president of clinical development at Quintiles (now QuintilesIMS), where she was responsible for all Phase I-IV clinical development operations globally, reaching $3 billion in annual revenue. During her time at Quintiles, Ms. Stafford was also a member of the Quintiles executive committee. In addition to her role at Novan, Ms. Stafford continues to participate in other professional activities, including serving as a director at Health Decisions, Inc. and adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at The University of North Carolina at Chapel Hill, and also maintains her third-party consulting business. She was named as one of the 10 top women in biotech by FierceBiotech in 2012, recognized as a Distinguished Alumna at UNC Chapel Hill in 2016, and recently designated an NACD Governance Fellow. She holds a Bachelor of Science and a Masters in Public Health, both from The University of North Carolina at Chapel Hill, with her specialization in Biostatistics.
Dr. Stasko is a co-founder, President and Chief Scientific Officer and a Director of Novan, Inc. Dr. Stasko has led the transformation of the Company’s nitric oxide platform from the academic benchtop to Phase 3 clinical trials and is considered a leading expert in the field of nitric oxide. He is an inventor of the core Novan technology and of more than 100 patent filings, 19 of which have issued, and has authored several peer-reviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide. Dr. Stasko has led the Company through each of its private financings totaling more than $100 million, as well as the award of government grants and contracts totaling $15 million, the latter ultimately resulting in Novan’s national recognition as a Tibbetts Award winner for excellence in Small Business Innovation Research. He has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise, who share his vision to position Novan as a commercially successful leader in the dermatology market.